Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Looking To Expand Urology/Gynecology Product Offerings

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific remains open to the possibility of making an acquisition in the urology or gynecology area to boost the current 8-10% rate of revenue growth.

You may also be interested in...



Boston Scientific Adds To Carotid Pipeline With Endotex Nexstent

Patient enrollment for a clinical trial evaluating Boston Scientific's Filterwire distal protection device with Endotex Interventional Systems' Nexstent carotid stent should begin by year-end.

Cook Looks To Reach Zenith In Endovascular AAA Market With Q3 PMA Filing

Cook, Inc. anticipates filing a premarket approval application with FDA in the third quarter of 2001 for its Zenith endovascular abdominal aortic aneurysm (AAA) graft, positioning the firm to become the third player in the endovascular AAA market behind Medtronic and Guidant.

Medtronic GuardWire Begins Controlled Roll-Out In U.S. Market

Medtronic PercuSurge is planning to submit an IDE application in the next two months for a 500-600 patient trial evaluating its GuardWire distal protection device in patients with acute myocardial infarction.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel